Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.60 AUD
Change Today 0.00 / 0.00%
Volume 43.3K
VLA On Other Exchanges
Symbol
Exchange
Berlin
OTC US
OTC US
As of 11:50 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

viralytics ltd (VLA) Snapshot

Open
A$0.61
Previous Close
A$0.60
Day High
A$0.63
Day Low
A$0.60
52 Week High
06/9/15 - A$0.93
52 Week Low
09/4/14 - A$0.27
Market Cap
110.5M
Average Volume 10 Days
154.4K
EPS TTM
A$-0.02
Shares Outstanding
184.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VIRALYTICS LTD (VLA)

Related News

No related news articles were found.

viralytics ltd (VLA) Related Businessweek News

No Related Businessweek News Found

viralytics ltd (VLA) Details

Viralytics Limited, a biotechnology company, engages in developing oncolytic immunotherapy treatments for a range of cancers in Australia. Its lead investigational product is CAVATAK, a proprietary formulation of the common cold Coxsackievirus Type A21 that is in Phase II clinical trial for the treatment of late-stage melanoma; Phase ½ multi-dose intravenous clinical trial for late-stage melanoma, non-small cell lung, bladder, and prostate cancer; Phase I clinical trial for non-muscle invasive bladder cancer; and Phase Ib combination clinical trial for late-stage melanoma. The company is also conducting various preclinical programs on CAVATAK the treatment of breast, multiple myeloma, pancreatic, and malignant glioma cancer, as well as for acute myeloid leukemia and chronic lymphocytic leukemia. In addition, it develops EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

viralytics ltd (VLA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$445.5K
Chief Financial Officer
Total Annual Compensation: A$150.8K
Compensation as of Fiscal Year 2015.

viralytics ltd (VLA) Key Developments

Viralytics Limited expected to report Fiscal Year 2015 results on September 3, 2015. This event was calculated by Capital IQ (Created on August 28, 2015).

Viralytics Limited expected to report Fiscal Year 2015 results on September 3, 2015. This event was calculated by Capital IQ (Created on August 28, 2015).

Viralytics Limited Announces Earnings Results for the Year Ended June 30, 2015

Viralytics Limited announced earnings results for the year ended June 30, 2015. The company reported net cash used in operating activities for the year was $4.5 million, cash position at the end of the year was $21.6 million and reported loss was $4.3 million.

Viralytics Limited Presents at Asia Biotech Invest 2015, May-20-2015 12:10 PM

Viralytics Limited Presents at Asia Biotech Invest 2015, May-20-2015 12:10 PM. Venue: Sheraton Hotel & Towers, Hong Kong. Speakers: Malcolm L. McColl, Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:AU A$0.60 AUD 0.00

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VLA.
View Industry Companies
 

Industry Analysis

VLA

Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.1x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRALYTICS LTD, please visit www.viralytics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.